The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
This article reviews current morbidity and mortality statistics for the major classes of primary brain tumors including malignant astrocytoma, glioblastoma, low-grade astrocytoma, oligodendroglioma, meningioma, and other benign tumors and metastatic tumors. Innovations in therapy are discussed for surgery, radiation, chemotherapy, and such newer areas as hyperthermia, immunotherapy, and phototherapy.
Salcman
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001254:Astrocytoma / Q000453:epidemiology; D001932:Brain Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D002330:Carmustine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004739:England; D004806:Ependymoma / Q000453:epidemiology; D005260:Female; D005909:Glioblastoma / Q000453:epidemiology; D006801:Humans; D006979:Hyperthermia, Induced; D007116:Immunization, Passive; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008527:Medulloblastoma / Q000453:epidemiology; D008579:Meningioma / Q000453:epidemiology; D008875:Middle Aged; D009837:Oligodendroglioma / Q000453:epidemiology; D014481:United States
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D002330:Carmustine